NCT06708624View on ClinicalTrials.gov

Ocular Safety and Usability Study for FYB201 PFS

PHASE4CompletedINTERVENTIONAL
Enrollment

31

Participants

Timeline

Start Date

June 11, 2024

Primary Completion Date

August 8, 2024

Study Completion Date

August 8, 2024

Conditions
Age-Related Macular DegenerationBranch Retinal Vein Occlusion with Macular EdemaCentral Retinal Vein Occlusion with Macular Edema
Interventions
DRUG

FYB201 0.5 mg (0.05 mL of 10 mg/mL)

IVT administration of FYB201 in a PFS

Trial Locations (4)

21740

Research Site, Hagerstown

90807

Research Site, Long Beach

95008

Research Site, Campbell

97477

Research Site, Eugene

Sponsors

Lead Sponsor

Formycon AG
All Listed Sponsors
lead

Formycon AG

INDUSTRY

NCT06708624 - Ocular Safety and Usability Study for FYB201 PFS | Biotech Hunter | Biotech Hunter